Sitryx Therapeutics

As major pharmaceutical companies continue investing heavily in immunology –with Sanofi’s recent $9.1bn acquisition of Blueprint Medicines underscoring the sector’s strategic importance – San Franci

Sanofi R&D chief Houman Ashrafian is very sympathetic to the plight of cash-strapped biotechs but has implored companies not to skimp financially on the design and development of their clinical pr

Anti-inflammatory drugs have come a long way since the advent of corticosteroids. While they marked a pivotal moment in the 20th century for managing devastating inflammation, non-steroidal anti-infla

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning